17 min
Linvoseltamab for Relapsed/Refractory Multiple Myeloma: Updates on LINKER-MM1 From AACR 2024 Oncology Data Advisor
-
- Science
In this interview from the American Association for Cancer Research (AACR) 2024 Annual Meeting, Dr. Alankrita Taneja, third-year Hematology/Oncology Fellow at Roswell Park Cancer Institute and Oncology Data Fellows Forum Member, speaks with Dr. Sundar Jagannath, Professor of Medicine (Hematology and Medical Oncology) and Director of the Center of Excellence for Multiple Myeloma at the Mount Sinai Icahn School of Medicine and Tisch Cancer Institute.
At the meeting, Dr. Jagannath presented results of the phase 1/2 LINKER-MM1 trial of linvoseltamab, a CD3-directed B-cell maturation antigen (BCMA) antibody under investigation for relapsed/refractory multiple myeloma. In this follow-up conversation, Dr. Jagannath shares further insights into the trial, including:
• The study design, which includes triple-class–refractory patients
• The unique dosing schedule of linvoseltamab, which reduces the frequency of administration to improve patient convenience
• The response, survival, and measurable residual disease (MRD) negativity outcomes demonstrated in the trial, including among high-risk patients
• Management of side effects, including cytokine release syndrome (CRS), neutropenia, anemia, and infections
• The future role of linvoseltamab in the treatment landscape for relapsed/refractory multiple myeloma as it advances through investigation
• And more!
In this interview from the American Association for Cancer Research (AACR) 2024 Annual Meeting, Dr. Alankrita Taneja, third-year Hematology/Oncology Fellow at Roswell Park Cancer Institute and Oncology Data Fellows Forum Member, speaks with Dr. Sundar Jagannath, Professor of Medicine (Hematology and Medical Oncology) and Director of the Center of Excellence for Multiple Myeloma at the Mount Sinai Icahn School of Medicine and Tisch Cancer Institute.
At the meeting, Dr. Jagannath presented results of the phase 1/2 LINKER-MM1 trial of linvoseltamab, a CD3-directed B-cell maturation antigen (BCMA) antibody under investigation for relapsed/refractory multiple myeloma. In this follow-up conversation, Dr. Jagannath shares further insights into the trial, including:
• The study design, which includes triple-class–refractory patients
• The unique dosing schedule of linvoseltamab, which reduces the frequency of administration to improve patient convenience
• The response, survival, and measurable residual disease (MRD) negativity outcomes demonstrated in the trial, including among high-risk patients
• Management of side effects, including cytokine release syndrome (CRS), neutropenia, anemia, and infections
• The future role of linvoseltamab in the treatment landscape for relapsed/refractory multiple myeloma as it advances through investigation
• And more!
17 min